Here is the detailed summary of the Merck (MRK) 4Q25 Earnings:
Revenue and Business Performance
Merck reported total sales of 16.4billion for the fourth quarter of 2025, representing a 5% increase compared to the same period last year. For the full year 2025, total sales reached 63.5billion, a 6% growth. This performance was primarily driven by the strength of the pharmaceutical segment, particularly in oncology and new product launches.
Core Product Dynamics
KEYTRUDA remains the company’s primary growth pillar, with fourth-quarter sales reaching 8.4billion, up 5%. This growth was fueled by strong uptake in early-stage cancer indications. Additionally, WINREVAIR, the newly launched treatment for pulmonary arterial hypertension, showed exceptional performance in 2025 with full-year sales of 1.4billion, establishing itself as a significant new revenue stream. Conversely, GARDASIL sales saw a substantial decline of 39% for the full year, dropping to 5.2billion, primarily due to decreased demand in the China market.
Financials and Profitability
GAAP net income for the fourth quarter was 2.96billion, a decrease from the previous year, largely due to fluctuations in R&D expenses and amortization of intangible assets related to acquisitions. Non-GAAP EPS for the quarter was 2.04, exceeding market expectations. The company maintained high R&D spending throughout 2025, reflecting its continued commitment to developing its pipeline.
Cash Flow and Capital Allocation
Cash flow from operating activities reached 15.2billion in 2025, with Free Cash Flow (FCF) at approximately 12.1billion. Merck demonstrated a proactive capital allocation strategy, focusing on dividend payments and strategic M&A. The company completed the acquisitions of Verona Pharma and Cidara Therapeutics during the year to strengthen its respiratory and infectious disease portfolios.
Future Outlook and Strategy
Merck provided an optimistic long-term outlook, projecting that potential commercial opportunities from new products could exceed 70billion by the mid-2030s. This strategic positioning aims to offset the eventual patent expiry of KEYTRUDA. For 2026, the company noted that the acquisition of Cidara will result in a one-time charge of approximately 3.65 per share, which will impact the upcoming year’s reported earnings.
Below is a detailed analysis of the Merck (MRK) 4Q25 Income Statement, focusing on the strategic drivers and financial health of the company.
Revenue Growth and Segment Drivers
- Top-line Performance: Total revenue for the quarter reached $16,400 million, a 5.0% increase year-over-year. Despite significant headwinds in the vaccine portfolio, the Pharmaceutical segment maintained steady growth (+5.7%), contributing 90.5% of total sales, underscoring the company’s heavy reliance on its drug portfolio.
- Keytruda Dominance: Sales grew to $8,372 million (+6.8% YoY), accounting for approximately 51% of Merck’s total revenue. Growth was primarily fueled by strong uptake in earlier-stage cancer indications, solidifying its role as the company’s primary “cash cow” as it approaches its patent expiration.
- Winrevair’s Surge: This newly launched pulmonary arterial hypertension (PAH) treatment contributed $467 million, a massive 133.5% increase compared to estimated prior levels. Winrevair is successfully proving to be a critical strategic pillar in diversifying revenue away from Keytruda.
- Vaccine Headwinds: Gardasil/Gardasil 9 sales plummeted 33.5% to $1,031 million. This sharp decline was almost entirely attributed to a significant drop in demand within the China market, marking it as the most significant negative factor in the 4Q25 report.
Profitability and Expense Structure (GAAP)
- Aggressive R&D Spending: GAAP R&D expenses surged by 85.0% to $3,886 million, representing 23.7% of total revenue. This spike was driven by business development activities, including the acquisitions of Verona Pharma and Cidara Therapeutics. Merck is clearly prioritizing the long-term pipeline over short-term GAAP margins.
- Cost of Sales Pressure: Cost of sales rose 44.9% YoY, making up 33.8% of revenue. This increase was primarily due to higher amortization of intangible assets from recent acquisitions and shifts in the product mix, which pressured GAAP gross margins.
- Net Income and EPS Divergence: GAAP Net Income fell 20.8% due to the high R&D investments and acquisition-related charges. However, the Non-GAAP EPS (which excludes these one-time items) rose 18.6% to $2.04, beating market expectations and demonstrating that the core business remains highly profitable.
Strategic Evaluation
Merck is currently in a high-stakes transition phase. While the “Keytruda patent cliff” remains a concern for the late 2020s, the rapid scaling of Winrevair and the aggressive acquisition strategy suggest a proactive approach to replacing lost revenue. The volatility in China for the vaccine business is a short-term risk, but the company’s long-term outlook—projecting over $70 billion in potential revenue from new products by the mid-2030s—remains the key benchmark for investors.
Based on the 4Q25 earnings report and the 2026 outlook, Merck’s pipeline strategy is focused on diversifying away from Keytruda as it approaches its patent cliff. The company now estimates that new growth drivers will contribute over $70 billion in non-risk adjusted annual sales by the mid-2030s.
1. Oncology: Defending the Franchise & Next-Gen ADCs
Merck is moving beyond PD-1 monotherapy toward combinations and targeted delivery systems.
- Keytruda Lifecycle Management (QLEX): The subcutaneous (SC) formulation received FDA approval in September 2025 for 38 indications. This is a crucial move to protect the franchise by shifting patients to a more convenient, patent-protected delivery method.
- ADC Partnership with Daiichi Sankyo:
- Ifinatamab deruxtecan (I-DXd): Phase 3 trials are ongoing for small cell lung cancer (SCLC).
- Patritumab deruxtecan (HER3-DXd): Advancing in Phase 3 for breast cancer.
- Datopotamab deruxtecan (Dato-DXd): Recently granted priority review in the U.S. for metastatic triple-negative breast cancer (TNBC).
- mRNA Cancer Vaccine: Developed with Moderna (mRNA-4157), this remains a high-potential program in Phase 3 for melanoma and NSCLC.
2. Cardiometabolic & Respiratory: The Second Growth Engine
This is the fastest-growing part of the pipeline, providing the most immediate revenue diversification.
- Winrevair (Sotatercept): A blockbuster in the making for Pulmonary Arterial Hypertension (PAH). It crossed the $1 billion sales threshold in 2025 and is expanding into earlier functional classes (WHO Group 1).
- Enlicitide (Oral PCSK9 Inhibitor): This is a potential “practice-changing” drug. Phase 3 CORALreef trial results (published Feb 2026) showed a ~60% reduction in LDL-C, matching the efficacy of current injectables but in an oral pill form. This is a multi-billion dollar opportunity targeting high-cholesterol patients.
- Ohtuvayre (Ensifentrine): Acquired via Verona Pharma, this first-in-class PDE 3/4 inhibitor for COPD is seeing rapid uptake since its 2025 launch.
3. Infectious Disease & Immunology
- MK-1406 (formerly CD388): A “once-per-season” antiviral for influenza prevention. Merck views this as a potential multi-billion dollar vaccine alternative for high-risk individuals.
- Cidara Acquisition: Completed in early 2026, adding rezafungin to the antifungal portfolio. While this caused a one-time charge of $3.65 per share, it strengthens Merck’s hospital-based infectious disease leadership.
- Islatravir: Ongoing Phase 3 studies for both HIV prevention and treatment in combination with other agents (e.g., lenacapavir).
4. Strategic Outlook for 2026
| Area | Key Milestone in 2026 | Impact |
| Enlicitide | Regulatory Filing | Entry into the massive oral lipid-lowering market. |
| Cidara Portfolio | Commercial Integration | Expansion into next-gen antifungal treatments. |
| Keytruda + Welireg | Adjuvant RCC Data | Extending Keytruda’s reach in renal cancer. |
| Tulisokibart (TL1A) | Phase 2b Readouts | Advancing into IBD and other immunology indications. |
Summary: Merck’s 2026 is a “make-or-break” year for the pipeline. While GAAP earnings are depressed by the massive $3.65/share acquisition charge for Cidara, the long-term roadmap is significantly stronger than it was a year ago, with the oral PCSK9 and Winrevair providing a clear path to replace Keytruda’s future revenue loss.
Based on the February 2026 earnings report and the official financial guidance issued by management, Merck (MRK) is entering a “transitional investment year.” While long-term prospects were upgraded, the short-term 2026 outlook came in below Wall Street expectations due to heavy acquisition-related charges and regional headwinds.
1. Key Financial Guidance (Full-Year 2026)
The company has provided the following range for the fiscal year ending December 31, 2026:
- Worldwide Sales: $65.5 billion to $67.0 billion (representing 1%–3% YoY growth).
- Non-GAAP EPS: $5.00 to $5.15 (a significant drop from $8.98 in 2025).
- Adjusted Gross Margin: Approximately 82%.
- Effective Tax Rate: 14% to 15%.
2. Strategic “Headwinds” Impacting 2026
The lower-than-expected earnings guidance is primarily driven by three factors:
- M&A One-Time Charge: The guidance reflects a $3.65 per share one-time charge related to the acquisition of Cidara Therapeutics. Excluding this massive business development charge, core earnings would be significantly higher.
- The “Januvia” Hit: Merck projects a $2.5 billion revenue headwind due to the loss of exclusivity (generic competition) and price negotiations under the Inflation Reduction Act (IRA) for its diabetes franchise, Januvia and Janumet.
- China Vaccine Slump: Sales of the HPV vaccine Gardasil are expected to remain under pressure. Management has notably stated they assume zero shipments to China in 2026 as the market digests excess inventory and faces increased local competition.
3. Growth Drivers (“Tailwinds”)
Despite the conservative 2026 guidance, several areas remain exceptionally strong:
- Oncology Leadership: Keytruda family sales (including the newly launched subcutaneous Keytruda Qlex) are expected to continue growing through 2028.
- Blockbuster Launch (Winrevair): Sales for the pulmonary arterial hypertension (PAH) drug are expected to scale rapidly, having already reached $1.4 billion in its first full year (2025).
- Animal Health: This segment remains a stable, non-cyclical cash generator, with growth projected in the mid-to-high single digits.
4. Long-Term Potential Upgrade
The highlight of the 2026 outlook was management’s increased confidence in the “post-Keytruda” era:
Merck now anticipates over $70 billion in potential non-risk-adjusted annual commercial opportunities by the mid-2030s. This is a $20 billion increase from the estimate provided just one year ago, driven by the oral PCSK9 program and the Daiichi Sankyo ADC partnership.
Source: https://www.merck.com/wp-content/uploads/sites/124/2026/02/4Q25-Merck-Earnings-Presentation.pdf
Back to Merck page